TRIHEXYPHENIDYL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trihexyphenidyl Hydrochloride, and when can generic versions of Trihexyphenidyl Hydrochloride launch?
Trihexyphenidyl Hydrochloride is a drug marketed by Mikart, Pharm Assoc, Pharm Ventures, Hikma, Natco Pharma Ltd, Novitium Pharma, Nylos, Vangard, and Watson Labs. and is included in thirteen NDAs.
The generic ingredient in TRIHEXYPHENIDYL HYDROCHLORIDE is trihexyphenidyl hydrochloride. There are three drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the trihexyphenidyl hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trihexyphenidyl Hydrochloride
A generic version of TRIHEXYPHENIDYL HYDROCHLORIDE was approved as trihexyphenidyl hydrochloride by WATSON LABS on December 31st, 1969.
Summary for TRIHEXYPHENIDYL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 13 |
Finished Product Suppliers / Packagers: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 105 |
Clinical Trials: | 4 |
Patent Applications: | 1,922 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRIHEXYPHENIDYL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TRIHEXYPHENIDYL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Taiwan University Hospital | Phase 4 |
Bachmann Strauss Dystonia & Parkinson Foundation, Inc. | |
University of Florida |